A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
T-Cell Therapy (ECT204) in Adults With Advanced HCC Post author: Post published:March 17, 2026 Post category: Continue ReadingT-Cell Therapy (ECT204) in Adults With Advanced HCC
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Post author: Post published:March 17, 2026 Post category: Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingStudy of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Post author: Post published:March 17, 2026 Post category: Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Post author: Post published:March 17, 2026 Post category: Continue ReadingPSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
